Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.